Prilosec gets extra exclusivity

Published: 30-Jun-2001


AstraZeneca's Prilosec (omeprazole) proton pump inhibitor has been given an extra six months' market exclusivity by the FDA as part of the organisation's programme to increase knowledge about the clinical efficacy of drugs in children. The exclusivity was granted in return for AstraZeneca providing information from a clinical study on the use of the drug in children aged from 1 month to 16 years. It is not currently indicated for use in children.

You may also like